Merrimack is developing a companion diagnostic for seribantumab to measure the levels of five proteins involved in the ErbB pathway and predicts the activated state of ErbB3 for the diagnosis of cancer (Filing 10-K , Merrimack, MAR 20, 2013, View Source [SID:1234501372]).
Merrimack is developing a companion diagnostics for use of MM-111, to identify overexpression levels of ErbB2 (HER2), ErbB3 and heregulin levels for the diagnosis of cancer

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


(Filing, Annual, Astex Pharmaceuticals, MAR 19, 2013, View Source [SID:1234503955])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


(Filing, 10-K, Cleveland BioLabs, MAR 18, 2013, View Source [SID:1234505708])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Bettering China’s biosimilars

Cancer, lymphoma, non-Hodgkin’s
IND submisson to SFDA in 2012 for the treatment of NHL (BioCentury, MAR 18, 2013). It is expected to complete its review in 2014.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cancer, leukemia, chronic lymphocytic
IND submisson to SFDA in 2012 for the treatment of chronic lymphocytic leukemia (BioCentury, MAR 18, 2013). It is expected to complete its review in 2014.

Cancer, arthritis, rheumatoid
IND submisson to SFDA in 2012 for the treatment of rheumatoid arthritis (BioCentury, MAR 18, 2013). It is expected to complete its review in 2014.

(Biocentury, Bettering China’s biosimilars, MAR 18, 2013, View Source [SID:1234502439])

(Filing, 10-K, ChemoCentryx, MAR 14, 2013, View Source [SID:1234502669])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!